Clinical Trial VICCPED12112


NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Principal Investigator(s)

Devang Pastakia


  • Protocol No. VICCPED12112
  • Open Date: 01/04/2013
  • Staging: Phase II
  • Age Group: Both Child and Adult
  • Scope: National
  • Objective: Correlation of urinary polyamine levels with progression of disease in neuroblastoma.
  • Disease Sites: Pediatric Solid Tumors; Neuroblastoma (Pediatrics)
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: DFMO
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01586260
  • Secondary Protocol No: NMTRC003



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.